RBC Capital Comments on Valeant (VRX) Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Drugmaker Valeant raises profit forecast; shares spike
May 9, 2017 7:11 AM EDTBy Ankur Banerjee and Rod Nickel
(Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) raised its 2017 earnings forecast and reported its first profit in six quarters, helped by a one-time tax gain, and its U.S. shares jumped nearly 21 percent.
The maker of Bausch + Lomb contact lenses and irritable bowel treatment Xifaxan is trying to regain investor confidence after investigations into its drug pricing and other business practices, such as its use of a specialty pharmacy, by multiple U.S. government agencies.
Laval, Quebec-based Valeant... More
